BONS ET MAUVAIS USAGES DES NOUVEAUX ANTICOAGULANTS

Abstract

Dabigatran etexilate, a direct thrombin inhibitor, rivaroxaban and apixaban, direct inhibitors of
factor Xa, are recorded in thromboprophylaxis in major orthopedic surgery (total prosthesis of
hip and knee in adults).
These three oral anticoagulants have also been studied in nonvalvular atrial fibrillation following the RE-LY, ROCKET and ARISTOTLE trials [1-3]. They would soon be registered in the treatment of acute venous thrombosis and in the prevention of recurrence. These new indications will be associated with long-term treatments, lasting several months or even years, while the duration of treatment
prophylactic in orthopedic surgery is 10 to 35 days.